Nanomedicine News

RSS
ONXEO Provides Update on Nanoparticle-Based Livatag Phase III Trial for Hepatocellular Carcinoma

ONXEO Provides Update on Nanoparticle-Based Livatag Phase III Trial for Hepatocellular Carcinoma

WHO Teleconference: Novavax Reports Top-Line Data from Ebola GP Recombinant Nanoparticle Vaccine Clinical Trial

WHO Teleconference: Novavax Reports Top-Line Data from Ebola GP Recombinant Nanoparticle Vaccine Clinical Trial

Cerulean Commences Dosing in CRLX101-Weekly Paclitaxel Phase 1b Clinical Trial for Relapsed Ovarian Cancer

Cerulean Commences Dosing in CRLX101-Weekly Paclitaxel Phase 1b Clinical Trial for Relapsed Ovarian Cancer

Novel Method Utilizes Nanoparticles and UV Light to Isolate, Extract Contaminants

Novel Method Utilizes Nanoparticles and UV Light to Isolate, Extract Contaminants

MIT Scholars Engaged in Nanomaterials Study for Drug Delivery, Biofuel Catalysts

MIT Scholars Engaged in Nanomaterials Study for Drug Delivery, Biofuel Catalysts

NanoLock Signs Agreement to License its Nano-Polymer Additive that Protects Against Microbial Infection

Sticky-Flare Nanotechnology Reveals RNA Misregulation in Living Cells

Sticky-Flare Nanotechnology Reveals RNA Misregulation in Living Cells

New Electron Microscopy Method Allows Nanoscale Studies of Breast Tumors in Their Native Liquid Environment

New Electron Microscopy Method Allows Nanoscale Studies of Breast Tumors in Their Native Liquid Environment

Nanoparticles May Help Tackle Acne

Nanoparticles May Help Tackle Acne

Remedium's Hemogrip Patch to Help Stop Bleeding Receives FDA Clearance

Remedium's Hemogrip Patch to Help Stop Bleeding Receives FDA Clearance

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.